Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. - Wikidata - wikimedia - TriplyDB

Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.

Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.

http://www.wikidata.org/entity/Q40490902

about

Regulation of immune cell function and differentiation by the NKG2D receptor Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches NKG2D ligands as therapeutic targets Advantages and applications of CAR-expressing natural killer cells NKG2D Ligands in Tumor Immunity: Two Sides of a Coin A review of the past, present, and future directions of neoplasia Coming of Age in the Life of Neoplasia: Where We Have Been and Where We Are Going The structure of the atypical killer cell immunoglobulin-like receptor, KIR2DL4.An six-amino acid motif in the alpha3 domain of MICA is the cancer therapeutic target to inhibit shedding Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis.MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue.New insights into the role of EMT in tumor immune escape.Interleukin 10 decreases MICA expression on melanoma cell surface.NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease Elevation of soluble major histocompatibility complex class I related chain A protein in malignant and infectious diseases in Chinese patients Transcriptional regulation of ULBP1, a human ligand of the NKG2D receptor.Neuroblastoma: developmental biology, cancer genomics and immunotherapy.NK cell-based immunotherapies in Pediatric Oncology.Neuroblastoma killing properties of Vδ2 and Vδ2-negative γδT cells following expansion by artificial antigen-presenting cells.Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint Blockade: A Potent Vaccine Strategy in a Mouse Neuroblastoma Model.Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions.Increased sMICA and TGFβ1 levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells.Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy.Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy.Soluble HLA-G: Are they clinically relevant?Immunotherapy of neuroblastoma: present, past and future.PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells.Interaction Between Polymorphisms of IFN-γ and MICA Correlated with Hepatocellular Carcinoma.Activation and self-tolerance of natural killer cells.Immunology and immunotherapy of neuroblastoma Regulation of ligands for the activating receptor NKG2D.DNA damage response and development of targeted cancer treatments.NK cell receptors and their ligands in leukemia.Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients.Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands.NKG2D ligands in tumor immunity.

P2860

Q24635093-BE43CA8E-AB0B-40F4-8A32-ED92C1099C2D Q26825652-7A4848DA-8DE4-49DE-8783-B1B5EF059C3A Q27014888-2BEAB2A2-6F7A-4BA4-B843-C71150E0D50A Q28080875-B471F4B3-AA1E-45CB-9466-A1BAF22E95DA Q28083832-AE5E043F-7E1B-4E0E-9F23-8D836B3237E8 Q28389391-1FFA1C3D-2926-4DD5-ABDD-361C8E22FDFC Q28389985-A033E572-D742-41AC-A9E4-B0B7E53C124D Q28395095-C2FCF28A-4666-491C-83A6-12CE5F395255 Q30372604-7265C26D-273F-455E-A8D8-ADAB9CBCF6D2 Q30489974-EB810C6E-4AA2-492A-8C97-B154EBF10178 Q30547087-3457CC28-4926-4EEA-A3DB-63DECE9C8FEA Q33639723-3473AC12-DE01-41B8-B77A-FA6104FE583B Q33869781-CD857A8C-1102-4C55-917F-8BBB45A8A615 Q34131549-9E51FBC7-1E7E-4921-A747-53F0030C6FD6 Q34132372-B2C0A469-FCAE-40D6-9B2C-50584D3F7614 Q34307792-A621A41E-EF27-42C0-8E21-8E94D0C4A230 Q34488774-00FB1DA6-06F9-4CFF-8E10-3580AC6ED084 Q34556241-88FCF5EB-0E7C-4FFE-84BD-5454AC64C5C0 Q35283020-ABFFA43D-23C5-4C96-84AE-ED68DB16C1F1 Q35600975-FA3C2E66-EDD5-4596-8846-69A7DB15D0E2 Q35654544-142DE903-4CBE-4155-9170-7684894AC0EC Q35664913-0DAE0BDB-E9DD-4C83-AFEB-9F4BFF2838E5 Q35799094-C179FE7A-2BFE-454F-95EA-A8F8A493F423 Q35847668-0AC312AC-BA27-4B02-AAB1-3603E7B2705C Q36110266-7DAC3498-8324-41D9-9978-998E51A37342 Q36114222-008DB29A-ABAC-4AF8-BF54-2E26D044592D Q36269694-76891011-DF54-446E-8C56-A321886AF86D Q36384011-1CDBAE28-32CC-48AF-902C-90D996F34189 Q36453273-6E5D28C1-6FA3-43A3-AE62-59B13F6205E1 Q36597354-0706F273-3E5A-4831-8258-08FAB09DFC2F Q36597374-5DA598A8-6604-4E17-89D6-F418DABA82C8 Q36603556-C0C78AAB-3661-4218-B90B-802A5751FC2A Q36652183-9C454B67-3D46-4D3B-AA6C-4B5757E5B03C Q36856798-0E2D3223-8A77-4537-9079-5BA47E3DF03E Q36872056-68C7753B-8107-430A-9E8D-96348BF06722 Q36939423-40D5ADF9-4AF3-49D7-B39F-A3D03E160210 Q37018656-42927D68-6E87-4CAB-B751-FCB6884207A1 Q37222064-3C754811-FFAB-42D6-8969-DB9C71043B92 Q37242917-1C8661B8-21C3-44D4-B27B-51921112C665 Q37287179-BB12DF28-F578-49E4-8D2D-A3CEBCDD2D56

P2860

Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.

http://www.wikidata.org/entity/Q40490902

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Downregulation and/or release ...... rategy of human neuroblastoma.

@en

type

label

Downregulation and/or release ...... rategy of human neuroblastoma.

@en

prefLabel

Downregulation and/or release ...... rategy of human neuroblastoma.

@en

P1433

Q40490902-4583CDFA-3301-4059-B10C-1DAF44108B85

P1476

Q40490902-99DE9415-E3A6-4A00-9A35-5AA73C1AD0C4

P2093

Q40490902-02C8035E-39FE-4E78-A351-F51DB1E08854

Q40490902-2D56089D-A950-499C-AD69-71D2E2517B6A

Q40490902-7FF063DC-A96D-4C47-AE7A-DC2033065C51

Q40490902-947A1FBD-FBDE-4AE6-B296-DC941F116628

Q40490902-AC0AAE4F-2449-4ADB-8D6F-94289360170D

Q40490902-CBF47C6C-DB20-42D8-B75F-7F813EDA9E0A

Q40490902-DAF403F6-4575-43F4-8E2D-40EE328C294A

Q40490902-EF64D945-3DF8-4F06-9D5C-5D8009B76AAB

Q40490902-F43B6B01-C836-46CF-B8C5-89642B604D1C

P2860

Q40490902-0A6A010E-28DE-4CDC-BDE0-9ADAE56E59F5

Q40490902-1EF4E4E2-5CB4-4CD4-A5BF-123F2E91475B

Q40490902-2CAE62E2-2B28-4562-B3D7-325F47016EDC

Q40490902-3932D8C7-BBC4-4D02-BDD1-7D81E9555BE6

Q40490902-3E4011BA-28DA-4F63-8EC2-49CE55CA9185

Q40490902-43311BBE-CFE8-4F28-8BFD-CD00452AD8A3

Q40490902-46890E31-9103-48B2-9ABA-F1C497924399

Q40490902-5C60BAB5-6970-4C01-8B07-D3D653A8A186

Q40490902-65525C32-8A64-4507-AD2A-75558A994110

Q40490902-8038B1A5-282E-4857-9480-AD849B26449D

P304

Q40490902-F556B937-AC60-4B75-8A5E-447A746D9A61

P31

Q40490902-20630A12-1AEC-4ABB-B66D-621F6E7C040B

P356

Q40490902-54400205-4570-4FC0-8192-F6B09F182240

P433

Q40490902-83054E7C-4FD9-4967-B148-81D7D0B4EBE2

P478

Q40490902-61A9AAAD-DA31-4252-BAC8-10C97CAA06FB

P50

Q40490902-8964283F-CAEF-4FD9-8FDF-3912A366201E

P577

Q40490902-250C5E5B-E2E4-4367-96D1-CC8FD8787EFB

P5875

Q40490902-D86C31DA-91EA-4C12-BAF3-3F772DAC497C

P698

Q40490902-F49B6AD0-A0CC-4D3E-B46E-153100BD3587

P932

Q40490902-93AB7D36-BC39-4E82-BAAF-F142780CD8D6

P356

P1433

P1476

Downregulation and/or release ...... rategy of human neuroblastoma.

@en

P2093

Alexander Steinle

http://www.w3.org/2001/XMLSchema#string

Claudio Gambini

http://www.w3.org/2001/XMLSchema#string

Daniela Pende

http://www.w3.org/2001/XMLSchema#string

Ignazia Prigione

http://www.w3.org/2001/XMLSchema#string

Irma Airoldi

http://www.w3.org/2001/XMLSchema#string

Isabella Levreri

http://www.w3.org/2001/XMLSchema#string

Marta Camoriano

http://www.w3.org/2001/XMLSchema#string

Soldano Ferrone

http://www.w3.org/2001/XMLSchema#string

Vito Pistoia

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA

ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor

Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family

Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity

Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium

In search of the 'missing self': MHC molecules and NK cell recognition

Biology of natural killer cells

International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma.

Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis.

Neuroblastoma: biological insights into a clinical enigma.

P304

558-568

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1593/NEO.04316

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Lizzia Raffaghello

P577

2004-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8179498

http://www.w3.org/2001/XMLSchema#string

P698

15548365

http://www.w3.org/2001/XMLSchema#string

P932

1531660

http://www.w3.org/2001/XMLSchema#string